
---

**SELF-STUDY TEST**

**Pulmonary Nuclear Medicine**

Questions are taken from the *Nuclear Medicine Self-Study Program I*, published by The Society of Nuclear Medicine

**DIRECTIONS**

The following items consist of a heading followed by numbered options related to that heading. Select those options you think are true and those that you think are false. Answers may be found on page 70.

**FIGURE 1.**

The $^{99mTc}$ DTPA aerosol and $^{99mTc}$ MAA perfusion images shown in Figure 1 were obtained from a 65-yr-old woman who had increasing shortness of breath. The aerosol images (each 100,000 counts requiring about 150 sec of imaging time) were obtained immediately before the perfusion images (each 400,000 counts requiring about 60 sec). True statements concerning these images include:

1. The central airways deposition indicates that the aerosol droplets were too large to penetrate into the periphery of the right lung.
2. The medial right lower lobe activity seen on the perfusion image probably is “shine-through” from right lower lobe aerosol deposition.
3. The scintigraphic findings are typical of those seen in patients who have undergone irradiation of the right hemithorax for lung cancer.

True statements regarding sarcoidosis include:

4. It is a systemic disorder associated with abnormalities of the immune system's response to an infectious agent.
5. Most patients with sarcoidosis develop progressive deterioration in pulmonary function as a result of extensive pulmonary fibrosis.
6. The pathologic finding in the lungs of patients with early sarcoidosis that is most directly related to pulmonary $^{67}$Ga uptake is alveolitis with granuloma formation.
7. Pulmonary function tests generally show progressive deterioration of lung reserve in patients with normal $^{67}$Ga pulmonary scintigrams.
8. The magnitude of $^{67}$Ga uptake in the lungs of patients with sarcoidosis has been shown to correlate with both the severity of pulmonary function abnormality and the radiographic severity of pulmonary fibrosis.

(continued on page 70)
ITEMS 1–3: Unilateral Pulmonary Hypoventilation and Hypoperfusion

ANSWERS: 1. F, 2, F, 3, F.

Central pulmonary airflow hyperdeposition of radioaerosols is frequently associated with poor peripheral penetration of activity. In fact, prior to the development of convenient methods to produce submicronic radioaerosol droplets, central "hot spots" secondary to impaction of large particles commonly led to poor delineation of peripheral air spaces. The anterior and posterior radioaerosol images shown in Figure 1 reveal a substantial amount of radioaerosol activity at and just above the carina. This activity extends laterally into the region of the left central bronchi. However, there is excellent uniform peripheral penetration of radioaerosol activity in the left lung. Only the right lung shows markedly diminished aerosol activity, with a patchy distribution. Radioaerosol activity, however, does reach the lung periphery in several areas. There is no central right-sided aerosol hyperdeposition, nor are "hot spots" seen in more peripheral zones of the right lung. The lack of right-sided central airflow hyperdeposition and the excellent penetration of activity to the outer zones of the left lung and the peripheral location of whatever activity has reached the right lung suggest that the aerosol particles were small enough to reach the lung periphery. The findings suggest that intrinsic pulmonary disease, present to a much greater extent in the right lung than the left, is responsible for the asymmetric deposition of activity, rather than central obstruction or central airflow turbulence. The central hyperdeposition in the trachea probably was caused by turbulent airflow, perhaps secondary to excessive mucus in the airways. The findings also demonstrate that centrally turbulent airflow will not prevent good penetration of submicronic radioaerosols to a well-ventilated lung in the absence of significant airflow blockade.

Because inhalation and imaging of the 99mTc-labeled radioaerosol generally is performed before injection and imaging of the 99mTc MAA, the possibility always exists that 99mTc aerosol activity could contribute to and degrade the perfusion images. When both studies are properly performed, however, this is not a clinical problem. On the average, only about 700–800 μCi of radioaerosol is deposited in the lungs after a typical inhalation period of 2–3 minutes. A typical 99mTc MAA dose of approximately 4 mCi yields a perfusion image to aerosol image count-rate ratio of about 5:1. Under these circumstances, only areas of focal aerosol hyperdeposition are likely to be seen on the "combined" aerosol-perfusion image, and even these areas usually are not prominent. In Figure 1, note that the count rate for the aerosol images alone was 100,000 counts per 150 sec (about 660 counts/sec). After 99mTc MAA injection, the count rate was 400,000 counts per 60 sec (about 6660 counts/sec). Hence, the net count rate from 99mTc MAA was 6000 counts/sec. In this patient, the count rate contributed by 99mTc MAA was nearly ten times the aerosol count rate, making significant "shine-through" of the aerosol activity most unlikely. It has been shown that such "shine-through" is not a problem even when the 99mTc MAA to 99mTc DTPA count-rate ratios are as low as 4:1 or 5:1. In this example, the left central airway activity still can be seen faintly on the perfusion images, as can tracheal activity and swallowed activity in the gastric fundus. The medial right lower lobe radioaerosol activity is not as intense as these foci on the original aerosol images. Accordingly, it is unlikely to be visible on the perfusion images. Thus, medial right lower lobe activity on the perfusion images more likely represents a region of maintained perfusion than an artifact caused by 99mTc aerosol activity.

The irregular and incomplete reduction of perfusion seen in this patient’s right lung is not at all typical of postradiation change. In irradiated patients, perfusion is reduced in uniform fashion throughout the irradiated region, which usually has a well-defined geometric shape. At the radiation doses usually employed for bronchogenic carcinoma (≥5000 rads midplane cumulative dose), perfusion is markedly reduced due to radiation-induced microvascular obliteration. Ventilation also may be reduced in the irradiated area, but usually it is much less affected than perfusion. When abnormal, ventilation studies typically reveal effects of reduced lung volume, and show a more uniform pattern of hypoventilation than seen in this image.

In this patient, Swyer–James’ syndrome (unilateral hyperlucent lung) had been diagnosed many years previously. The origin of her disease was not known precisely, although she did report several episodes of bronchitis in childhood. Her chest radiograph revealed a moderately hyperlucent right lung and a normal-appearing left lung. The hypoventilation of her right lung was considered to be secondary to diffuse small airways obstructive disease on the right.

ITEMS 4–8: Sarcoidosis

ANSWERS: 4, F, 5, 6, T, 7, F, 8, F.

Sarcoidosis is a systemic disorder characterized by enhanced local immune processes, which cause the most significant morbidity through their effects on the pulmonary parenchyma. Although the etiology of sarcoidosis is still unknown, and no direct relationship to an infectious agent has been shown, there appears to be a temporal association between the presence of an initial alveolitis and the subsequent development of granulomas and fibrosis. In most patients disease is self-limited and is associated with a good prognosis. Patients who present with symptoms of dyspnea are those who have more advanced disease, the greatest extent of pulmonary fibrosis, and who show the poorest response to therapy. Prognosis is partially determined by the appearance of the disease on chest roentgenograms. Nonetheless, many patients with persistently abnormal roentgenograms show no clinical evidence of progressive disease.

Although granulomas are the characteristic pathologic feature of the disease, the initial lesion in the lung is probably an alveolitis from which the granulomas eventually are derived. As a granuloma matures, there is an increase in the number of fibroblasts, which may lead to roentgenographically evident parenchymal fibrosis. The sarcoid granuloma either resolves, leaving no morphologic changes, or it undergoes an obliterator
fibrosis, a process leading to widespread interstitial fibrosis, bronchiolitis, and distortion of pulmonary architecture. Gallium-67 images of the lungs are frequently abnormal in patients with pulmonary sarcoidosis. There is evidence from in vitro experiments that the macrophages associated with the alveolitis and granulomas of the active disease become labeled with more 67Ga on a per-cell basis than do normal macrophages. Furthermore, this increased macrophage uptake of 67Ga in vitro correlates with the presence of positive 67Ga scintigrams.

Although the role of 67Ga scintigraphy, as a means to stage or monitor the disease is controversial, patients with normal studies generally have stable pulmonary function, suggesting that their diseases are quiescent. Conversely, positive 67Ga studies have been associated with deterioration of pulmonary function in most, but not all, patients. Furthermore, several authors have demonstrated a close correlation between positive gallium scintigrams and responsiveness to therapy. Most authors seem to agree that corticosteroid therapy is unlikely to benefit a patient with sarcoidosis who has a negative 67Ga study. On the other hand, it appears that positive 67Ga scintigrams do not reliably distinguish patients who will improve spontaneously (without treatment) from those who require medical intervention.

Thus, it appears that 67Ga uptake marks the presence of one or more components of the disease stages associated with active alveolitis and granuloma formation. Gallium-67 localization has not been associated with pulmonary fibrosis per se, and hence may not correlate closely with pulmonary function or with the appearance of the chest roentgenogram. Patients who have pulmonary fibrosis but no 67Ga localization are unlikely to benefit from corticosteroid therapy, which appears to be most successful during the inflammatory phase of the disorder.

**References**


For further in-depth information, refer to the syllabus pages in Nuclear Medicine Self-Study I.
Residency Programs in Nuclear Medicine

Eva V. Dubovsky, M.D., Ph.D.
Division of Nuclear Medicine
University of Alabama Hospital
619 19th Street South
Birmingham, AL 35294
Tel: (205) 934-2140
Fax: (205) 934-5589

Teresita Angtuaco, M.D.
University of Arkansas for Medical Sciences
4301 West Markham (Slot 581)
Little Rock, AR 72205
Tel: (800) 626-7709

James M. Woolfenden, M.D.
Health Services Center
Division of Nuclear Medicine
University of Arizona
1501 North Campbell Avenue
Tucson, AZ 85724
Tel: (602) 626-7709

Randall A. Hawkins, M.D., Ph.D.
Division of Nuclear Medicine and Biophysics
UCLA School of Medicine
Los Angeles, CA 90024
Tel: (310) 825-5450
Fax: (310) 206-4899

Michael E. Siegel, M.D.
Department of Nuclear Medicine
LAC-USC Medical Center
1200 North State Street
Los Angeles, CA 90033
Tel: (213) 226-7858
Fax: (213) 226-2280

Lalitha Ramanna, M.D.
Cedars-Sinai Medical Center
8070 Beverly Blvd.
Los Angeles, CA 90048
Tel: (310) 855-4216

William H. Blahd, M.D.
Department of Veterans Affairs
Medical Center West Los Angeles
Wadsworth Division W115
Wilshire & Sawtelle Blvds.
Los Angeles, CA 90073
Tel: (310) 824-3130
Fax: (310) 824-6952

Norah Milne, M.D.
VA Medical Center Nuclear Medicine Service
5901 East 7th Street
Long Beach, CA 90822
Tel: (310) 494-5566
Fax: (310) 494-5972

Roger Sevlin, M.D.
Department of Nuclear Medicine
VA Medical Center

16111 Plummer Street
Sepulveda, CA 91343
Tel: (818) 895-9332
Fax: (818) 895-5829

William L. Ashburn, M.D.
Division of Nuclear Medicine
University Hospital, U.C. Medical Center
225 Dickinson Street (H-738)
San Diego, CA 92103
Tel: (619) 543-6680
Fax: (619) 543-1975

I. Ross McDougall, M.D., Ph.D.
Division of Nuclear Medicine
RM H0115
Stanford University Medical Center
Stanford, CA 94305
Tel: (415) 723-6882
Fax: (415) 723-8590

D. K. Shelton, M.D.
University of California
Davis Medical Center
2315 Stockton Blvd.
Sacramento, CA 95817
Tel: (916) 734-2754
Fax: (916) 734-7936

David Price, M.D.
Department of Nuclear Medicine
University of California, San Francisco
Nuclear Medicine, Rm L-340
3rd & Parnassus Aves, Box 0252
San Francisco, CA 94143-0252
Tel: (415) 476-1521
Fax: (415) 476-0616

Robert J. Lull, M.D.
Department of Nuclear Medicine
San Francisco General Hospital
1001 Potrero Avenue
Bldg 100, Rm 157
San Francisco, CA 94110
Tel: (415) 206-8580
Fax: (415) 206-6929

James L. Lear, M.D.
University of Colorado Health Science Center

This list includes all AMA-approved residency programs in nuclear medicine. An "X" in the column to the left of the program indicates an opening in the 1993 program. Almost all open programs begin in July. Please contact programs directly for further information. This listing has been prepared under the auspices of the Academic Council.
Residency Programs in Nuclear Medicine

X George Sfakianakis, M.D.  
Division of Nuclear Medicine  
Jackson Memorial Hospital  
1611 North West 12th Avenue  
Miami, FL 33101  
Tel: (305) 585-7955  
Fax: (305) 585-0014

X John Vansant, M.D.  
Nuclear Medicine Division  
Emory University Hospital  
1364 Clifton Road NE  
Atlanta, GA 30310  
Tel: (404) 727-4843  
Fax: (404) 727-3899

X Peter T. Kirchner, M.D., Director  
The University of Iowa Hospitals & Clinics  
Division of Nuclear Medicine  
Department of Radiology  
Iowa City, IA 52242-1009  
Tel: (319) 356-4302  
Fax: (319) 356-2220

X Robert E. Henkin, M.D.  
Foster G. McGraw Hospital  
Loyola University of Chicago  
2160 South 1st Avenue  
Maywood, IL 60153  
Tel: (708) 216-9425  
Fax: (708) 216-5813

X William G. Spies, M.D.  
Department of Nuclear Medicine  
Northwestern Memorial Hospital  
250 East Superior Street  
Chicago, IL 60611  
Tel: (312) 908-2514  
Fax: (312) 908-8118

X Ernest W. Fordham, M.D.  
Rush-Presbyterian-St. Luke's Medical Center  
1653 West Congress Parkway  
Chicago, IL 60612  
Tel: (312) 942-5757  
Fax: (312) 942-2114

X Carlos Bekerman, M.D., FACNP  
Division of Nuclear Medicine  
Michael Reese Medical Center  
2929 South Ellis Avenue  
Chicago, IL 60616  
Tel: (312) 791-2525  
Fax: (312) 808-7571

X Henry N. Wellman, M.D.  
Indiana University Medical Center  
University Hospital  
Division of Nuclear Medicine  
550 North University Blvd.—Rm. 0663  
Indianapolis, IN 46202-5250  
Tel: (317) 274-8832  
Fax: (317) 274-1806

X Ralph G. Robinson, M.D.  
Division of Nuclear Medicine  
Kansas University Medical Center  
39th & Rainbow Blvd.  
Kansas City, KS 66103  
Tel: (913) 588-6805  
Fax: (913) 588-7789

X Gary R. Conrad  
Department of Diagnostic Radiology  
University of Kentucky  
800 Rose Street  
Lexington, KY 40536-0084  
Tel: (606) 233-6585  
Fax: (606) 258-2171

X Edwin L. Palmer, M.D.  
Massachusetts General Hospital  
32 Fruit Street  
Boston, MA 02114  
Tel: (617) 726-8350  
Fax: (617) 726-6165

X S. James Adelstein, M.D., Ph.D.  
Harvard Medical School  
25 Shattuck Street  
Boston, MA 02115  
Tel: (617) 732-6289  
Fax: (617) 432-0173

X Henry N. Wagner, Jr., M.D.  
Division of Nuclear Medicine  
John Hopkins Hospital  
615 North Wolfe Street—Rm. 2001  
Baltimore, MD 21205  
Tel: (410) 955-3350  
Fax: (410) 955-6222

X James C. Reynolds, M.D.  
National Institute of Health  
Clinical Center  
9000 Rockville Pike Bldg 10IC-496  
Bethesda, MD 20892-0010  
Tel: (301) 496-5675  
Fax: (301) 496-0114

X Eugene D. Silverman, M.D.  
Division of Nuclear Medicine  
National Naval Medical Center  
Baltimore, MD 20889-5011  
Tel: (301) 295-4982

X David E. Kuhl, M.D.  
Chief, Division of Nuclear Medicine  
University of Michigan Medical Center  
B I G 412, Box 0028  
1500 East Medical Center Drive  
Ann Arbor, MI 48109-0028  
Tel: (313) 936-5388  
Fax: (313) 936-8182

X Howard J. Dworkin, M.D.  
Division of Nuclear Medicine  
William Beaumont Hospital  
3601 West Thirteen Mile Road  
Royal Oak, MI 48072  
Tel: (313) 551-4128  
Fax: (313) 551-0768

X Kastytis C. Karvelis, M.D.  
Nuclear Medicine Residency Program  
Henry Ford Hospital  
2799 West Grand Blvd.  
Detroit, MI 48202  
Tel: (313) 876-3436  
Fax: (313) 876-1087

X Robert J. Boudeau, M.D., Ph.D.  
Division of Nuclear Medicine  
University of Minnesota Hospital  
Box 382 UMHC  
Minneapolis, MN 55455  
Tel: (612) 626-5912  
Fax: (612) 626-8495

X James L. Littlefield, M.D.  
St. Louis University Hospital  
VA Medical Center, 115JC  
915 North Grand Avenue  
St. Louis, MO 63106-1697  
Tel: (314) 289-6348  
Fax: (314) 289-6533

X Barry A. Siegel, M.D.  
Mallinckrodt Institute of Radiology  
Washington University School of Medicine  
510 South Kingshighway  
St. Louis, MO 63110  
Tel: (314) 362-2809  
Fax: (314) 362-2806

X Amolak Singh, M.D.  
Columbia Medical Center  
University of Missouri-Columbia  
Medical Center  
2-N19 Medical Science  
1 Hospital Drive  
Columbia, MO 65212  
Tel: (314) 882-7955  
Fax: (314) 882-1886

X Glenn V. Dalrymple, M.D.  
Department of Radiology  
University of Nebraska Medical Center  
600 South 42nd Street  
Omaha, NE 68198  
Tel: (402) 559-6188  
Fax: (402) 559-4675

X Hussein Abdel-Dayem, M.D.  
Division of Nuclear Medicine  
St. Vincent's Hospital  
153 West 11th Street  
Chicago, IL 60610  
Tel: (312) 944-1000  
Fax: (312) 944-2241

28A  
The Journal of Nuclear Medicine • Vol. 34 • No. 1 • January 1993
Residency Programs in Nuclear Medicine

New York, NY 10011
Tel: (212) 780-8782
Fax: (212) 675-1840

Joseph Sanger, M.D.
NYU Medical Center
560 Fifth Avenue
New York, NY 10016
Tel: (212) 263-7410
Fax: (212) 263-8137

Steven M. Larson, M.D.
Samuel D. J. Yeh, M.D.
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Tel: (212) 693-7371
Fax: (212) 717-3263

Barbara L. Binkert, M.D.
Division of Nuclear Medicine
RM St. 221
New York Hospital
525 East 69th Street
New York, NY 10021
Tel: (212) 746-4586
Fax: (212) 746-8873

E. Gordon DePuey, M.D.
St. Luke’s Roosevelt Hospital Center.
425 West 113th Street
New York, NY 10025
Tel: (212) 523-3398
Fax: (212) 523-3416

Josef Machac, M.D.
Department of Physics/Nuclear Medicine
Mt. Sinai Medical Center
One Gustave L. Levy Place
Box 1141
New York, NY 10029
Tel: (212) 241-4040

Ronald L. Van Heurten, M.D.
Presbyterian Hospital
622 West 168th Street
New York, NY 10032
Tel: (212) 305-7132
Fax: (212) 305-4244

David M. Mistein, M.D.
Albert Einstein College of Med.
1300 Morris Park Ave.
Bronx, NY 10461
Tel: (212) 904-4058
Fax: (212) 904-2354

Donald Margouleff, M.D.
North Shore University Hospital
300 Community Drive
Manhasset, NY 11030
Tel: (516) 562-4400
Fax: (516) 562-1608

Christopher J. Palestro, M.D.
Division of Nuclear Medicine
Long Island Jewish Medical Center.
New Hyde Park, NY 11042
Tel: (718) 470-7080
Fax: (718) 470-9247

John L. Bateman, M.D.
Veterans Affairs Medical Center
Middleville Road
Northport, NY 11768
Tel: (516) 216-4400 Ext. 7348
Fax: (516) 261-4400 Ext. 2722

F. Deaver Thomas, M.D.
Department of Nuclear Medicine
SUNY Health Science Center
at Syracuse University Hospital
750 East Adams Street
Syracuse, NY 13210
Tel: (315) 464-7031
Fax: (315) 464-7068

Joseph A. Prezio, M.D.
Department of Nuclear Medicine
State University of NY at Buffalo
105 Parker Hall, 3435 Main Street
Buffalo, NY 14214
Tel: (716) 838-5889
Fax: (716) 838-4918

Robert E. O’Mara, M.D.
Division of Nuclear Medicine
Strong Memorial Hospital
601 Elmwood Avenue
Rochester, NY 14642
Tel: (716) 275-4741
Fax: (716) 271-8698

Robert J. Cowan, M.D.
North Carolina Baptist Hospital
Department of Nuclear Medicine
Medical Center Blvd.
Winston-Salem, NC 27157-1088
Tel: (919) 716-4932
Fax: (919) 716-2029

R. Edward Coleman, M.D.
Division of Nuclear Medicine
Division of Imaging, Department of Radiology
Duke University Medical Center
Durham, NC 27710
Tel: (919) 660-2711 Ext. 5244
Fax: (919) 681-5636

Edward B. Silberstein, M.D.
University of Cincinnati Hospital
EL Saenger Radioisotope Lab
234 Goodman St. St. ML #577
Cincinnati, OH 45267
Tel: (513) 558-4282
Fax: (513) 558-7690

E. William Allen, M.D.
Oklahoma Memorial Hospital & Clinics
P.O. Box 26307
Oklahoma City, OK 73126
Tel: (405) 271-5141
Fax: (405) 271-3533

G. T. Krishnamurthy, M.D.
Oregon Health Sciences University
VA Medical Center. (115)
P.O. Box 1034
Portland, OR 97207
Tel: (503) 273-5023
Fax: (503) 273-5208

Gilbert H. Isacs, M.D.
Allegheny General Hospital
320 East North Avenue
Pittsburgh, PA 15212
Tel: (412) 359-3455
Fax: (412) 323-8310

Ajit N. Shaha, M.D.
Nuclear Medicine
Presbyterian-University Hospital
DeSoto at O’Hara St.
Pittsburgh, PA 15213
Tel: (412) 647-7391
Fax: (412) 647-6805

Simin Dadparvar, M.D.
Nuclear Medicine Department
MS-309 Hahnemann University Hospital
Broad and Vine Streets
Philadelphia, PA 19102-1192
Tel: (215) 762-7678
Fax: (215) 246-5926

Abass Alavi, M.D.
Department of Radiology
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Tel: (215) 662-3069
Fax: (215) 349-5843

Chan H. Park, M.D.
Thomas Jefferson University Hospital
11th and Walnut Streets
Philadelphia, PA 19107
Tel: (215) 955-6707
Fax: (215) 955-5331
Residency Programs in Nuclear Medicine

Alan H. Maurer, M.D.
Temple University Hospital
3401 North Broad Street
Philadelphia, PA 19140
Tel: (215) 221-8269

Frieda Silva DeRoldan, M.D.
University of Puerto Rico Medical Sciences Campus
G. P. O. Box 5067
San Juan, PR 00936
Tel: (809) 767-0382
Fax: (809) 767-0382

Leonie Gordon, M.D.
Kenneth M. Spicer, M.D., PhD
Division of Nuclear Medicine
Medical University of South Carolina
171 Ashley Avenue
Charleston, SC 29425
Tel: (803) 792-4021
Fax: (803) 792-9503

Martin P. Sandler, M.D.
Division of Nuclear Medicine
Vanderbilt University
RR 1219-MCN
Nashville, TN 37232-2405
Tel: (615) 343-3585
Fax: (615) 322-3764

Karl F. Hubner, M.D.
The University of Tennessee Graduate School of Medicine
1924 Alcoa Hwy
Knoxville, TN 37920-6999
Tel: (615) 544-9662
Fax: (615) 544-8883

William A. Erdman, M.D.
Department of Radiology
University of Texas Southwestern Medical School
5323 Harry Hines Blvd.

Dallas, TX 75235-9071
Tel: (214) 688-8022
Fax: (214) 688-2678

Warren H. Moore, M.D.
Department of Radiology
Baylor College of Medicine
One Baylor Plaza
Houston, TX 77030
Tel: (713) 791-3126
Fax: (713) 791-3363

Martin L. Nusynowitz, M.D.
Department of Radiology/Division of Nuclear Medicine
University of Texas Medical Branch Hospital
Galveston, TX 77550-2780
Tel: (409) 772-2921
Fax: (409) 772-3229

Ralph Blumhardt, M.D.
Fred L. Weiland, M.D.
Department of Radiology
University of Texas Health Science Center
7703 Floyd Curl Drive
San Antonio, TX 78284-7800
Tel: (210) 567-5600
Fax: (210) 567-6418

LTC Albert J. Moreno, M.D.
Division of Nuclear Medicine
William Beaumont Army Medical Center
El Paso, TX 79920-5001
Tel: (915) 569-2656

Frederick L. Datz, M.D.
University of Utah Medical Center
50 North Medical Drive
Salt Lake City, UT 84132
Tel: (801) 581-2716

Timothy Burke, M.D.
Medical College of Virginia Hospital
P.O. Box 1, MCV Station
Richmond, VA 23298-0481
Tel: (804) 786-6828
Fax: (804) 225-4181

Wil B. Nelp, M.D.
Division of Nuclear Medicine
RC-70
University of Washington
Seattle, WA 98195
Tel: (206) 786-6828
Fax: (206) 548-4496

David L. Yuille, M.D.
Division of Nuclear Medicine
St. Luke's Hospital
2900 West Oklahoma Ave.
Milwaukee, WI 53215
Tel: (414) 649-6418
Fax: (414) 649-7203

Arthur Z. Krasnow, M.D.
Division of Nuclear Medicine
Milwaukee Country Medical Complex
Box 104
8700 West Wisconsin Ave.
Milwaukee, WI 53226
Tel: (414) 257-6061
Fax: (414) 257-8129

Scott B. Perlman, M.D.
Division of Nuclear Medicine
University of Wisconsin Hospital & Clinics
600 Highland Avenue
Madison, WI 53792
Tel: (608) 262-7014
Fax: (608) 256-1901 Ext. 1434
I. EDITORIAL POLICY

The Journal of Nuclear Medicine publishes material of interest to the practitioners and scientists in the broad field of nuclear medicine. Proffered articles describing original laboratory or clinical investigations, case reports, technical notes and letters to the editor will be considered for publication. From time to time invited articles, editorials, and reviews of selected topics will be published. Manuscripts, including illustrations and tables, must be original and not under consideration by another publication.

The Journal of Nuclear Medicine has agreed to receive manuscripts in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," as cited in the following sources: *Ann Intern Med* (1988; 108:258–265) and *Br Med J* (1988; 296:401–405). In preparing manuscripts, authors should follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," and specific author instructions detailed below. Also, helpful guidance in conforming to the "Uniform Requirements" may be found in *Medical Style & Formats: An International Manual for Authors, Editors, and Publishers* by Edward J. Huth, MD (Philadelphia: ISI Press; 1987).

II. MANUSCRIPT SUBMISSION

Submit one original and three copies of the manuscript and four copies of the figures to:

H. William Strauss, MD, Editor-in-Chief
The Journal of Nuclear Medicine
Room 5406, MGH-East
Building 149, Thirteenth Street,
Charlestown, MA 02129

The Journal’s phone number is (617)726-5785. Original manuscripts will not be accepted by Facsimile, but for other communications the Fax number is (617)726-5708.

All manuscripts should be accompanied by a covering letter from the author responsible for correspondence regarding the manuscript. The covering letter should contain the following copyright disclosure statement in compliance with the Copyright Revision Act of 1976, effective January 1, 1978.

_Upon acceptance by The Journal of Nuclear Medicine, all copyright ownership for the article ______________________________ is transferred to The Society of Nuclear Medicine. We, the undersigned co-authors of this article, have contributed significantly to and share in the responsibility for the release of any part or all of the material contained within the article noted above. The undersigned stipulate that the material submitted to The Journal of Nuclear Medicine is new, original and has not been submitted to another publication for concurrent consideration._

We also attest that any human and/or animal studies undertaken as part of the research from which this manuscript was derived are in compliance with regulations of our institution(s) and with generally accepted guidelines governing such work.

We further attest that we have herein disclosed any and all financial or other relationships which could be construed as a conflict of interest, and that all sources of financial support for this study have been disclosed and are indicated in the acknowledgement.

This statement must be signed by all of the listed co-authors.

Copyright requirements do not apply to work prepared by United States government employees as part of their official duties.

You may suggest, in your cover letter, individuals who could serve as reviewers for your manuscript.

The covering letter should also contain a statement that the manuscript has been seen and approved by all authors and should give any additional information which may be helpful to the Editor. If there has been any prior publication of any part of the work, this should be acknowledged and appropriate written permission included. If color illustrations are included, a statement that the author(s) is (are) willing to assume the cost of color separation and reproduction is requested.

III. REVIEW PROCEDURE

Submitted manuscripts are reviewed for originality, significance, adequacy of documentation, reader interest, and composition.

Manuscripts not submitted according to author instructions will be returned to the author for correction prior to beginning the peer review process.

All manuscripts received for review are evaluated by a minimum of two reviewers. It is unusual for a manuscript to be accepted for publication without first undergoing a process of revision. Revised manuscripts are judged on the adequacy of responses to suggestions and criticisms made during the initial review.

All accepted manuscripts are subject to editing for scientific accuracy and clarity by the office of the Editor-in-Chief.

IV. FORMAT REQUIREMENTS

A. General Requirements

Manuscripts must be written in English. Whenever there is any doubt, authors should seek the assistance of experienced, English-speaking medical editors. A medical editor should review the final draft of the original and any revisions of the manuscript.

Type the manuscript on white bond paper, 8½ × 11 in. (21.6 × 27.9 cm), with margins of at least 1½ in. (4 cm). Type on one side of the paper only, double spacing every page. Begin each of the following sections on separate pages and in the following order: title page, abstract, text, acknowledgments, references, tables (each on a separate page), and legends. Number pages consecutively, beginning with the title page. Type the name of the senior author and page number in the upper right-hand corner of each page.

B. Title Page

The title page of the manuscript should include: (1) concise and informative title (less than 200 characters); (2) short running head or footnote of no more than 40 characters (letters and spaces) placed at the bottom of the title page and identified; (3) complete byline, with first name, middle initial, and last name of each author and highest academic degree(s), up to ten authors may be cited; (4) complete affiliation for each author, with the name of department(s) and institution(s) to which the work should be attributed; (5) disclaimer, if any; (6) name, address, and telephone number of one author responsible for correspondence about the manuscript; and (7) name and address of author to whom reprint requests should be directed, or statement that reprints are not available from the author. Financial support for the work should be noted in a statement on this page.

C. Abstract

An abstract of no more than 250 words should state the purpose of the study or investigation, basic procedures (study subjects or experimental animals and observational and analytic methods), major findings (specific data and their statistical significance, if not too lengthy), and the principal conclusions. Emphasize new and important aspects of the study or observations. No abbreviations or reference citations are to be used in the abstract.

D. Text

- Presentation

The text of _Original Scientific and Methodology Articles_ is usually divided into the following sections: Introduction, Materials and Methods, Results, Discussion, and Summary or Conclusion. The text of original scientific papers, exclusive of the abstract, legends, tables and references, should not exceed 5000 words.

_Case Reports_ should contain a concise description of no more than 1250 words, exclusive of the abstract, legends, tables and references, illustrated with no more than 3 figures, emphasizing the nuclear medicine aspects and including methodology, data, and correlative studies.

Letters should concern previously published material or matters of general interest and should be brief and to the point. All material is subject to editing. Letters commenting on previously published articles should be received within one year of the date of the referenced article’s publication. Letters should contain no more than 10 references.

In general, reference should not be made in the text to institutions or locations except when germane to that particular article. Generic names should be used throughout the text. Identify instruments and radiopharmaceuticals by manufacturer name and address in parentheses and describe procedures in sufficient detail to allow other investigators to reproduce the results.

- References

References should be cited in consecutive numerical order at first mention in the text and designated by the reference number underlined and in parentheses. References appearing in a table or figure should be numbered sequentially with those in the text.
Information for Authors

The Reference list must be typed double-spaced and numbered consecutively, as in the text. The Journal follows Index Medicus style for references and abbreviates journal names according to the List of Journals Indexed in Index Medicus. "Unpublished observations" and "personal communications" should not be used as references, although written—not verbal—communications may be noted as such in the text. References cited as "in press" must have been accepted and not merely in preparation or submitted. The author is responsible for the accuracy of all references and must verify them against the original document.

For journal articles, list all authors when six or less; for seven or more authors, list the first three and et al:


For books and book chapters, follow the examples below:


-Units of Measurement

The Journal requests that all measurements be listed in SI units. Older conventions may be used after the SI units, but should be placed in parentheses.

-Abbreviations and Symbols

With the exception of units of measurement, The Journal of Nuclear Medicine discourages the use of abbreviations. For additional information on proper medical abbreviations, consult the CBE Style Manual, Fifth Edition (Bethesda, MD: Council of Biology Editors, 1983). When an abbreviation is used it should be preceded by the full word or name of the item being abbreviated.

E. Figures

-Tables

Type each table double-spaced on a separate page. Do not submit tables as photographs. Tables should be self-explanatory and should supplement, not duplicate, the text. Each table must be cited in consecutive numerical order in the text. Number the tables consecutively with an arabic number following the word TABLE. The titles should be descriptive, brief, and typed centered in upper- and lower-case letters. Place horizontal rules below the title, column headings, and at the end of the table. Do not use vertical lines. Give each column a short or abbreviated heading.

Place explanatory matter in footnotes, not in the heading. Use the following symbols, in this sequence: *, †, §, ¶, ‡, **. Expand in the footnote all non-standard abbreviations used in each table. Identify footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. If data from another published source are used, obtain written permission from the publisher of the original source and acknowledge fully. If data from an unpublished source are used, obtain permission from the principal investigator, and acknowledge fully.

-Illustrations

Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, the selection of sharp, high-quality illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement.

Submit four complete sets of glossy illustrations, no smaller than 3 1/2 × 5 in. or larger than 8 × 10 in. Do not send original artwork. Glossy photographs of line drawings rendered professionally on white drawing paper in black India ink, with template or typeset lettering, should be submitted. No hand-drawn or typewritten art will be accepted. Letters, numbers, and symbols (typeset or template) must be clear and of sufficient size to retain legibility after reduction.

Each illustration must be numbered and cited in consecutive order in the text. Illustrations should be identified on a gummed label affixed to the back of each illustration, and containing the following information: figure number, part of figure (if more than one), senior author's name, and designation of "top."

Color illustrations will be considered for publication, but the author is responsible for all charges relating to separations and printing. An estimate of these charges will be sent to the author at the time of production. Author approval of charges is required before production will continue. Four complete sets of glossy color photographs (not transparencies) must be submitted for review. Polaroid prints are not acceptable.

All submitted illustrations become the property of The Society of Nuclear Medicine and will not be returned unless the manuscript is rejected.

-Legends for Illustrations

Legends for illustrations should be concise and should not repeat the text. Legends should be typed double-spaced on a separate page. Each figure should be cited in consecutive numerical order in the text. Number the figures with an arabic number following the word FIGURE. Use letters to designate parts of illustrations (e.g., A, B, C) and describe each part clearly in the legend. Any letter designations or arrows appearing on the illustration should be identified and described fully.

Original (not previously published) illustrations are preferred for publication in the Journal; however, if illustrations have been published previously, authors are responsible for obtaining written permission from the publisher to reprint. The source of the original material must be cited in the references and the following credit line included in the legend: (Reprinted by permission of Ref. X.) All permission releases must be submitted to the Editor at the time of manuscript submission.

F. Acknowledgements

Acknowledge persons or agencies contributing substantially to the work, including any grant support.

V. MANUSCRIPT CHECKLIST

Original double-spaced typed manuscript and 3 copies.

Four sets of unmounted glossy Figures (no smaller than 3 1/2 × 5 in. or larger than 8 × 10 in.).

Copyright transfer.

Title page with title, authors' names, and complete affiliations; corresponding author, complete address, and telephone number; author for reprint requests and complete address.

Abstract (maximum, 250 words).

References in consecutive numerical order. Reference list typed double-spaced.

Figures and Tables in consecutive numerical order.

Legends for all Figures; typed double-spaced.

Consent forms for patient photographs.

Written permission from the publisher to reprint previously published Figures and Tables.
### Advertisers for January 1993:

<table>
<thead>
<tr>
<th>No.</th>
<th>Company Name</th>
<th>City, State</th>
<th>Phone Number</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ADAC Laboratories</td>
<td>Milpitas, CA</td>
<td>(800) 538-8531</td>
<td>43A</td>
</tr>
<tr>
<td>2</td>
<td>American College of Nuclear Physicians</td>
<td>Washington, DC</td>
<td>(202) 857-1135</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>AMR</td>
<td>Milford, CT</td>
<td>(203) 877-1610</td>
<td>42A</td>
</tr>
<tr>
<td>4</td>
<td>Bioscan</td>
<td>San Marcos, CA</td>
<td>(800) 255-7226</td>
<td>15A</td>
</tr>
<tr>
<td>5</td>
<td>Biodex Medical Systems</td>
<td>Shirley, NY</td>
<td>(516) 924-9000</td>
<td>6A</td>
</tr>
<tr>
<td>6</td>
<td>Capintec, Inc.</td>
<td>Ramsey, NJ</td>
<td>(800) 631-3826</td>
<td>2A</td>
</tr>
<tr>
<td>7</td>
<td>Diversified Diagnostic Products, Inc.</td>
<td>Houston, TX</td>
<td>(713) 955-5323</td>
<td>38A</td>
</tr>
<tr>
<td>8</td>
<td>Du Pont Company</td>
<td>Billerica, MA</td>
<td>(800) 225-1572</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Encore Medical Systems</td>
<td>Palantine, IL</td>
<td>(708) 359-4400</td>
<td>15A</td>
</tr>
<tr>
<td>10</td>
<td>Elscint, Inc.</td>
<td>Hackensack, NJ</td>
<td>(800) 228-7226</td>
<td>9A-11A</td>
</tr>
<tr>
<td>11</td>
<td>Medimatic Div. of M.I.D., Inc.</td>
<td>New York, NY</td>
<td>(212) 688-5620</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Nuclear Medicine Consulting Firm</td>
<td>Greenville, PA</td>
<td>(800) 682-2226</td>
<td>19A</td>
</tr>
<tr>
<td>13</td>
<td>SNM Meetings</td>
<td>Pages 12A, 33A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>SNM Membership Information</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### From:

Your Name: ____________________________ Title: ____________________________

Institution: __________________________ Dept: ____________________________

Address: ____________________________

City: ____________________________ State: __________ Zip: __________________

Phone: ____________________________ FAX: ____________________________

Primary Specialty: ____________________ Secondary Specialty: ____________________

### Circle One Answer In Each Category:

#### Employer

1. Hospital:
   a. 500 patients plus
   b. 300-499 patients
   c. 200-299 patients
   d. 100-199 patients
2. Private Clinic
3. R&D Commercial
4. University
5. Government
6. Other ____________________________

#### Purchase Authority

1. Recommend
2. Specify
3. Purchase

#### Reason for Inquiry

1. Immediate Purchase
2. General Information
3. Budgeting Information

#### SNM Member

1. Yes
2. No

#### SNM Subscriber

1. Yes
2. No